Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Zhao, AT; Pirsl, F; Steinberg, SM; Holtzman, NG; Schulz, E; Mina, A; Mays, JW; Cowen, EW; Comis, LE; Joe, GO; Yanovski, JA; Pavletic, SZ.
Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease.
Bone Marrow Transplant. 2023; 58(12):1377-1383
Doi: 10.1038/s41409-023-02097-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Schulz Eduard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with chronic graft-versus-host disease (cGVHD) are at heightened risk for components of metabolic syndrome (MetS), yet the prevalence and impact of MetS in the cGVHD patient population remain unknown. Adult patients (n = 229) with cGVHD enrolled in the cross-sectional NIH cGVHD Natural History Study (NCT00092235) were evaluated for MetS at enrollment and for variables associated with MetS. A majority (54.1%, 124/229) of the cohort met the diagnostic criteria for MetS. Patients with higher body mass index and lower performance status scores were more likely to have MetS (P < 0.0001; P = 0.026; respectively). Higher circulating erythrocyte sedimentation rate, C-reactive protein, and creatinine concentrations, along with lower estimated glomerular filtration rate, were associated with MetS (P < 0.001; P < 0.004; P = 0.02; P = 0.002; respectively). Patients with MetS compared to patients without MetS had no statistical differences in survival or NRM (5-year OS: 64% [95% CI: 54.8-71.8%] vs. 75.1% [95% CI: 65.6-82.3%]; respectively; overall P = 0.20; 5-year NRM: 21.7% [95% CI: 13.6-30.9%] vs. 10.1% [95% CI: 4.4-18.7%]; respectively; overall P = 0.12). Additionally, there was no difference in cGVHD severity between the two groups. Given the high prevalence of MetS in this cohort, clinicians should screen for its presence before it develops into comorbidities that complicate the course of cGVHD treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Humans - administration & dosage
- Bronchiolitis Obliterans Syndrome - administration & dosage
- Metabolic Syndrome - epidemiology, etiology
- Prevalence - administration & dosage
- Cross-Sectional Studies - administration & dosage
- Graft vs Host Disease - etiology
- Chronic Disease - administration & dosage
- Hematopoietic Stem Cell Transplantation - adverse effects